Pancreatic Fungal Communities Are Linked to Pancreatic Cancer.

DOI: https://doi.org/10.1158/2159-8290.CD-RW2019-155

IF: 28.2

2019-10-11

Cancer Discovery

Abstract:The mycobiome influences cancer progression in mouse models of pancreatic ductal adenocarcinoma.

Medicine,Biology,Environmental Science

What problem does this paper attempt to address?

Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response.

Yihan Chai,Zhengze Huang,Xuqiu Shen,Tianyu Lin,Yiyin Zhang,Xu Feng,Qijiang Mao,Yuelong Liang

DOI: https://doi.org/10.3390/microorganisms11051240

IF: 4.5

2023-01-01

Microorganisms

Abstract:The microbiota is present in many parts of the human body and plays essential roles. The most typical case is the occurrence and development of cancer. Pancreatic cancer (PC), one of the most aggressive and lethal types of cancer, has recently attracted the attention of researchers. Recent research has revealed that the microbiota regulates PC carcinogenesis via an altered immune response. Specifically, the microbiota, in several sites, including the oral cavity, gastrointestinal tract, and pancreatic tissue, along with the numerous small molecules and metabolites it produces, influences cancer progression and treatment by activating oncogenic signaling, enhancing oncogenic metabolic pathways, altering cancer cell proliferation, and triggering chronic inflammation that suppresses tumor immunity. Diagnostics and treatments based on or in combination with the microbiota offer novel insights to improve efficiency compared with existing therapies.
Fungi accelerate pancreatic cancer

Ivy M. Dambuza,Gordon D. Brown

DOI: https://doi.org/10.1038/d41586-019-02892-y

IF: 64.8

2019-10-02

Nature

Abstract:The communities of microorganisms that occupy specific regions of the body are often altered in cancer<a href="#ref-CR1">1</a>, and these microbiomes — particularly their bacterial components — are a current focus of cancer research. One example is pancreatic ductal adenocarcinoma (PDA), for which changes in the bacterial community occupying the pancreas have been documented<a href="#ref-CR2">2</a>. This lethal disease often goes undetected until it has reached advanced stages, and the prognosis is usually very poor<a href="#ref-CR3">3</a>. <a href="https://doi.org/10.1038/s41586-019-1608-2">Writing in Nature,</a> Aykut et al.<a href="#ref-CR4">4</a> reveal that the fungal component of the pancreatic microbiome (known as the mycobiome) is also altered in PDA. In fact, an abundance of a specific fungal genus actually promotes the disease.

multidisciplinary sciences
A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors

Jared Klug,Marissa Mesko,Xiling Shen,Anders B. Dohlman,Iris H. Gao,Steven M. Lipkin,Iliyan D. Iliev

DOI: https://doi.org/10.1016/j.cell.2022.09.015

IF: 64.5

2022-09-29

Cell

Abstract:Fungal microorganisms (mycobiota) comprise a small but immunoreactive component of the human microbiome, yet little is known about their role in human cancers. Pan-cancer analysis of multiple body sites revealed tumor-associated mycobiomes at up to 1 fungal cell per 10 4 tumor cells. In lung cancer, Blastomyces was associated with tumor tissues. In stomach cancers, high rates of Candida were linked to the expression of pro-inflammatory immune pathways, while in colon cancers Candida was predictive of metastatic disease and attenuated cellular adhesions. Across multiple GI sites, several Candida species were enriched in tumor samples and tumor-associated Candida DNA was predictive of decreased survival. The presence of Candida in human GI tumors was confirmed by external ITS sequencing of tumor samples and by culture-dependent analysis in an independent cohort. These data implicate the mycobiota in the pathogenesis of GI cancers and suggest that tumor-associated fungal DNA may serve as diagnostic or prognostic biomarkers.

cell biology,biochemistry & molecular biology
Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations

Zhou Chen,Shaofeng Zhang,Shi Dong,Hao Xu,Wence Zhou

DOI: https://doi.org/10.3389/fimmu.2022.844401

IF: 7.3

2022-03-03

Frontiers in Immunology

Abstract:The human body is thoroughly colonized by a wide variety of microorganisms, termed microbiota. Pancreatic cancer, one of the most aggressive forms of cancer, is no exception. The microbiota of pancreatic cancer largely influences and even dominates the occurrence, development and outcome of pancreatic cancer in many ways. Studies have shown that microbiota could change the malignant phenotype and prognosis of pancreatic cancer by stimulating persistent inflammation, regulating the antitumor immune system, changing the tumor microenvironment and affecting cellular metabolism. This is why the association of the microbiota with pancreatic cancer is an emerging area of research that warrants further exploration. Herein, we investigated the potential microbial markers of pancreatic cancer, related research models, the mechanism of action of microbiota in pancreatic cancer, and pancreatic cancer-microbiota-related treatment.

immunology
Fungi complements cancer

Anna Dart

DOI: https://doi.org/10.1038/s41568-019-0218-5

IF: 78.5

2019-10-15

Nature Reviews Cancer

Abstract:The microbiome is more than just bacteria. Now, the groups of Deepak Saxena and George Miller at New York University have linked alterations in the fungal component of the pancreatic microbiome, which activate the complement cascade, to pancreatic ductal adenocarcinoma growth and progression

oncology
The Microbiota and Microbiome in Pancreatic Cancer: More Influential Than Expected

Weiwei Miao,Si Shi,Chen Liang,Qing-Cai Meng,Jie Hua,Yi-Yin Zhang,Jiang Liu,Bo Zhang,Jin Xu,Lei Yu

DOI: https://doi.org/10.1186/s12943-019-1008-0

IF: 37.3

2019-01-01

Molecular Cancer

Abstract:Microbiota is just beginning to be recognized as an important player in carcinogenesis and the interplay among microbes is greater than expected. Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease for which mortality closely parallels incidence. Early detection would provide the best opportunity to increase survival rates. Specific well-studied oral, gastrointestinal, and intrapancreatic microbes and some kinds of hepatotropic viruses and bactibilia may have potential etiological roles in pancreatic carcinogenesis, or modulating individual responses to oncotherapy. Concrete mechanisms mainly involve perpetuating inflammation, regulating the immune system-microbe-tumor axis, affecting metabolism, and altering the tumor microenvironment. The revolutionary technology of omics has generated insight into cancer microbiomes. A better understanding of the microbiota in PDAC might lead to the establishment of screening or early-stage diagnosis methods, implementation of cancer bacteriotherapy, adjustment of therapeutic efficacy even alleviating the adverse effects, creating new opportunities and fostering hope for desperate PDAC patients.
Microbiome and pancreatic ductal adenocarcinoma

Annemilaï Tijeras-Raballand,Marc Hilmi,Lucile Astorgues-Xerri,Rémy Nicolle,Ivan Bièche,Cindy Neuzillet

DOI: https://doi.org/10.1016/j.clinre.2020.101589

Abstract:Pancreatic ductal adenocarcinoma (PDAC) incidence and related-deaths are increasing worldwide. PDAC is characterized by poor prognosis due to late diagnosis, high metastatic capacity and resistance to therapy. This is partially due to its specific microenvironment, where the stroma is prominent over tumor cells. Besides the oral and gut microbiota, the intratumor microbiome, i.e. the bacterial and fungal microorganisms present within the tumor, was recently introduced as a new partner of the tumor microenvironment of PDAC modulating pancreatic carcinogenesis, intratumor immune infiltrates, and response to chemotherapy. In this review, we propose an overview of current knowledge about the roles of bacteria and fungi in PDAC development and biology, and discuss potential therapeutic implications.
Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development

Ruben Bellotti,Cornelia Speth,Timon E Adolph,Cornelia Lass-Flörl,Maria Effenberger,Dietmar Öfner,Manuel Maglione

DOI: https://doi.org/10.3390/cancers13143431

2021-07-08

Abstract:Background: Dysbiosis of the intestinal flora has emerged as an oncogenic contributor in different malignancies. Recent findings suggest a crucial tumor-promoting role of micro- and mycobiome alterations also in the development of pancreatic ductal adenocarcinoma (PDAC). Methods: To summarize the current knowledge about this topic, a systematic literature search of articles published until October 2020 was performed in MEDLINE (PubMed). Results: An increasing number of publications describe associations between bacterial and fungal species and PDAC development. Despite the high inter-individual variability of the commensal flora, some studies identify specific microbial signatures in PDAC patients, including oral commensals like Porphyromonas gingivalis and Fusobacterium nucleatum or Gram-negative bacteria like Proteobacteria. The role of Helicobacter spp. remains unclear. Recent isolation of Malassezia globosa from PDAC tissue suggest also the mycobiota as a crucial player of tumorigenesis. Based on described molecular mechanisms and interactions between the pancreatic tissue and the immune system this review proposes a model of how the micro- and the mycobial dysbiosis could contribute to tumorigenesis in PDAC. Conclusions: The presence of micro- and mycobial dysbiosis in pancreatic tumor tissue opens a fascinating perspective on PDAC oncogenesis. Further studies will pave the way for novel tumor markers and treatment strategies.
Intratumour microbiome of pancreatic cancer

Shi-Wei Guan,Quan Lin,Hai-Bo Yu

DOI: https://doi.org/10.4251/wjgo.v15.i5.713

2023-05-15

World J Gastrointest Oncol

Abstract:Pancreatic cancer is a high mortality malignancy with almost equal mortality and morbidity rates. Both normal and tumour tissues of the pancreas were previously considered sterile. In recent years, with the development of technologies for high-throughput sequencing, a variety of studies have revealed that pancreatic cancer tissues contain small amounts of bacteria and fungi. The intratumour microbiome is being revealed as an influential contributor to carcinogenesis. The intratumour microbiome has been identified as a crucial factor for pancreatic cancer progression, diagnosis, and treatment, chemotherapy resistance, and immune response. A better understanding of the biology of the intratumour microbiome of pancreatic cancer contributes to the establishment of better early cancer screening and treatment strategies. This review focuses on the possible origins of the intratumour microbiome in pancreatic cancer, the intratumour localization, the interaction with the tumour microenvironment, and strategies for improving the outcome of pancreatic cancer treatment. Thus, this review offers new perspectives for improving the prognosis of pancreatic cancer.
Abstract 2176: Differences in gut microbial composition alter pancreatic tumorigenesis

Rian M. Howell,Jose Enriquez Ortiz,Olivia Le Roux,Vidhi Chandra,Le Li,Pratip K. Bhattacharya,Florencia McAllister

DOI: https://doi.org/10.1158/1538-7445.am2024-2176

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer-related deaths by 2030, and currently has a 5-year survival rate of roughly 10%. With long-term survival rates in patients being exceedingly low, understanding what factors delineate survival is imperative. When comparing spontaneous transgenic mouse models of pancreatic cancer housed in geographically distinct vivaria, regardless of a common lineage, we observed drastically different phenotype states in the respective locations. We hypothesize that the gut microbiome results in different gene expression profiles, leading to alterations in pancreatic tumorigenesis. Using various sequencing techniques, including 16s rRNA and RNA sequencing of the gut, we identified unique signatures at these respective institutions. Subsequent fecal microbiota transplantation and single bacterial species colonization experiments were performed to evaluate the ability of microbiomes/specific microbiota to alter the rate of tumorigenesis. In addition to probing the gut microbiome, circulating metabolites from individual mice were quantified, and correlated to phenotype state. Following identification of potentially tumorigenic bacterially derived metabolites, single bacteria colonization experiments were utilized to determine the downstream effects of identified metabolites as well as the ability of directly altering the metabolic landscape to drive tumorigenesis. Additionally, murine derived pancreatic cancer cells were exposed to both identified bacteria alone or bacterially produced metabolite and analyzed by metrics such as proliferation and relative expression of transcription factors associated with cancer development in vitro. Taken together, these data demonstrate the ability of distinct gut microbiomes to directly alter the metabolic landscape in mice, thus differentially altering the progression of pancreatic lesions. By better understanding the factors that stratify survivorship, we can begin to employ clinically actionable methodologies in the treatment or prevention of pancreatic cancer. Citation Format: Rian M. Howell, Jose Enriquez Ortiz, Olivia Le Roux, Vidhi Chandra, Le Li, Pratip K. Bhattacharya, Florencia McAllister. Differences in gut microbial composition alter pancreatic tumorigenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2176.

oncology
Mycobiome and Cancer: What Is the Evidence?

Natalia Vallianou,Dimitris Kounatidis,Gerasimos Socrates Christodoulatos,Fotis Panagopoulos,Irene Karampela,Maria Dalamaga

DOI: https://doi.org/10.3390/cancers13133149

2021-06-24

Cancers

Abstract:Background: To date, most researchhas focused on the bacterial composition of the human microbiota. In this review, we synopsize recent data on the human mycobiome and cancer, highlighting specific cancer types based on current available evidence, presenting interesting perspectives and limitations of studies and laboratory methodologies. Recent findings: Head and neck cancer carcinoma (HNCC), colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDA) have been associated with dissimilarities in the composition of mycobiota between cancer cases and non-cancer participants. Overall, fungal dysbiosis with decreased fungal richness and diversity was common in cancer patients; however, a specific mycobiotic signature in HNSCC or CRC has not emerged. Different strains of Candida albicans have been identified among cases with HNCC, whilst Lichtheimia corymbifera, a member of the Mucoraceae family, has been shown to predominate among patients with oral tongue cancer. Virulence factors of Candida spp. include the formation of biofilm and filamentation, and the secretion of toxins and metabolites. CRC patients present a dysregulated ratio of Basidiomycota/Ascomycota. Abundance of Malassezia has been linked to the occurrence and progression of CRC and PDA, particularly in animal models of PDA. Interestingly, Schizophyllum, a component of the oral mycobiome, may exhibit anti-cancer potential. Conclusion: The human mycobiome, per se, along with its interactions with the human bacteriome and the host, may be implicated in the promotion and progression of carcinogenesis. Fungi may be used as diagnostic and prognostic/predictive tools or treatment targets for cancer in the coming years. More large-scale, prospective, multicentric and longitudinal studies with an integrative multi-omics methodology are required to examine the precise contribution of the mycobiome in the etiopathogenesis of cancer, and to delineate whether changes that occur in the mycobiome are causal or consequent of cancer.

oncology
Microbiomes in pancreatic cancer can be an accomplice or a weapon

Xiaoyu Guo,Pan Wang,Yuan Li,Yawei Chang,Xiaobing Wang

DOI: https://doi.org/10.1016/j.critrevonc.2024.104262

IF: 6.625

2024-01-10

Critical Reviews in Oncology/Hematology

Abstract:Recently, several investigations have linked the microbiome to pancreatic cancer progression. It is critical to reveal the role of different microbiomes in the occurrence, development, and treatment of pancreatic cancer. The current review summarizes the various microbiota types in pancreatic cancer while updating and supplementing the mechanisms of the representative gut, pancreatic, and oral microbiota, and their metabolites during its pathogenesis and therapeutic intervention. Several novel strategies have been introduced based on the tumor-associated microbiome to optimize the early diagnosis and prognosis of pancreatic cancer. The pros and cons involving different microbiomes in treating pancreatic cancer are discussed. The microbiome-related clinical trials for pancreatic cancer theranostics are outlined. This convergence of cutting-edge knowledge will provide feasible ideas for developing innovative therapies against pancreatic cancer.

oncology,hematology
Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models

Ryan M Thomas,Raad Z Gharaibeh,Josee Gauthier,Mark Beveridge,Jillian L Pope,Maria V Guijarro,Qin Yu,Zhen He,Christina Ohland,Rachel Newsome,Jose Trevino,Steven J Hughes,Mary Reinhard,Kathryn Winglee,Anthony A Fodor,Maria Zajac-Kaye,Christian Jobin

DOI: https://doi.org/10.1093/carcin/bgy073

2018-05-28

Carcinogenesis

Abstract:Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States yet data are scant regarding host factors influencing pancreatic carcinogenesis. Increasing evidence support the role of the host microbiota in carcinogenesis but its role in PDAC is not well established. Herein, we report that antibiotic-mediated microbial depletion of KrasG12D/PTENlox/+ mice showed a decreased proportion of poorly differentiated tumors compared to microbiota-intact KrasG12D/PTENlox/+ mice. Subsequent 16S rRNA PCR showed that ~50% of KrasG12D/PTENlox/+ mice with PDAC harbored intrapancreatic bacteria. To determine if a similar observation in humans correlates with presence of PDAC, benign and malignant human pancreatic surgical specimens demonstrated a microbiota by 16S bacterial sequencing and culture confirmation. However, the microbial composition did not differentiate PDAC from non-PDAC tissue. Furthermore, murine pancreas did not naturally acquire a pancreatic microbiota, as germ-free mice transferred to specific pathogen-free housing failed to acquire intrapancreatic bacteria over time, which was not augmented by a murine model of colitis. Finally, antibiotic-mediated microbial depletion of Nod-SCID mice, compared to microbiota-intact, showed increased time to PDAC xenograft formation, smaller tumors, and attenuated growth. Interestingly, both xenograft cohorts were devoid of intratumoral bacteria by 16S rRNA PCR, suggesting that intrapancreatic/intratumoral microbiota is not the sole driver of PDAC acceleration. Xenografts from microbiota-intact mice demonstrated innate immune suppression by immunohistochemistry and differential regulation of oncogenic pathways as determined by RNA sequencing. Our work supports a long-distance role of the intestinal microbiota on PDAC progression and opens new research avenues regarding pancreatic carcinogenesis.

oncology
Fusobacterium nucleatum induces pancreatic cancer cell proliferation and migration by regulating host autocrine and paracrine signaling

Barath Udayasuryan,Tam T. D. Nguyen,Ariana Umaña,Raffae N. Ahmad,LaDeidra Monét Roberts,Polina Sobol,Stephen D. Jones,Jennifer M. Munson,Daniel J. Slade,Scott S. Verbridge

DOI: https://doi.org/10.1101/2021.11.19.469245

2021-11-19

Abstract:Abstract Pancreatic ductal adenocarcinoma (PDAC) harbors a complex tumor microbiome that has been implicated in cancer progression and resistance to chemotherapy. Recent clinical investigations uncovered a correlation between high loads of intratumor Fusobacterium nucleatum and decreased patient survival. Here we show that healthy and cancerous pancreatic cell lines harboring intracellular F. nucleatum secrete increased levels of cancer-associated cytokines including GM-CSF, CXCL1, IL-8, and MIP-3α. We report that GM-CSF (granulocyte-macrophage colony stimulating factor) secretion directly increases the proliferation and migration of pancreatic cancer cells via an autocrine mechanism, notably in the absence of immune cell participation. Furthermore, we show that non-cancerous pancreatic epithelial cells do not exhibit increased proliferation or migration in response to these cytokines, but nevertheless, their secreted cytokines stimulate these responses in cancerous cell lines through paracrine signaling. Our results provide evidence that intratumor F. nucleatum in the pancreas elicits an infection-specific cytokine secretion profile from both normal and cancerous cells that adversely contributes to cancer progression through autocrine and paracrine mechanisms. Therefore, these results support the importance of investigating the contributions of both microbiome and host driven processes in pancreatic cancer to guide future therapeutic interventions.
Revisiting the intrinsic mycobiome in pancreatic cancer

Ashley A. Fletcher,Matthew S. Kelly,Austin M. Eckhoff,Peter J. Allen

DOI: https://doi.org/10.1038/s41586-023-06292-1

IF: 64.8

2023-08-03

Nature

Abstract:arising from: B. Aykut et al. Nature https://doi.org/10.1038/s41586-019-1608-2 (2019)

multidisciplinary sciences
An investigation for phylogenetic characterization of human Pancreatic cancer microbiome by 16SrDNA Sequencing and Bioinformatics techniques

Colby Hunter,Khadimou Dia,Julia Boykins,Karrington Perry,Narendra Banerjee,Jazmine Cuffee,Erik Armstrong,Gabrielle Morgan,Hirendra Nath Banerjee,Anasua Banerjee,Santanu Bhattacharya

DOI: https://doi.org/10.21203/rs.3.rs-4140368/v1

2024-03-25

Abstract:Pancreatic cancer is a significant public health concern, with increasing incidence rates and limited treatment options. Recent studies have highlighted the role of the human microbiome, particularly the gut microbiota, in the development and progression of this disease. Microbial dysbiosis, characterized by alterations in the composition and function of the gut microbiota, has been implicated in pancreatic carcinogenesis through mechanisms involving chronic inflammation, immune dysregulation, and metabolic disturbances. Researchers have identified specific microbial signatures associated with pancreatic cancer, offering potential biomarkers for early detection and prognostication. By leveraging advanced sequencing and bioinformatics tools, scientists have delineated differences in the gut microbiota between pancreatic cancer patients and healthy individuals, providing insights into disease pathogenesis and potential diagnostic strategies. Moreover, the microbiome holds promise as a therapeutic target in pancreatic cancer treatment. Interventions aimed at modulating the microbiome, such as probiotics, prebiotics, and fecal microbiota transplantation, have demonstrated potential in enhancing the efficacy of existing cancer therapies, including chemotherapy and immunotherapy. These approaches can influence immune responses, alter tumor microenvironments, and sensitize tumors to treatment, offering new avenues for improving patient outcomes and overcoming therapeutic resistance. Overall, understanding the complex interplay between the microbiome and pancreatic cancer is crucial for advancing our knowledge of disease mechanisms and identifying innovative therapeutic strategies. Here we report phylogenetic analysis of the 16S microbial sequences of the pancreatic cancer mice microbiome and corresponding age matched healthy mice microbiome. We successfully identified differentially abundance of microbiota in the pancreatic cancer.
Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

Erick Riquelme,Yu Zhang,Liangliang Zhang,Maria Montiel,Michelle Zoltan,Wenli Dong,Pompeyo Quesada,Ismet Sahin,Vidhi Chandra,Anthony San Lucas,Paul Scheet,Hanwen Xu,Samir M. Hanash,Lei Feng,Jared K. Burks,Kim-Anh Do,Christine B. Peterson,Deborah Nejman,Ching-Wei D. Tzeng,Michael P. Kim,Cynthia L. Sears,Nadim Ajami,Joseph Petrosino,Laura D. Wood,Anirban Maitra,Ravid Straussman,Matthew Katz,James Robert White,Robert Jenq,Jennifer Wargo,Florencia McAllister

DOI: https://doi.org/10.1016/j.cell.2019.07.008

IF: 64.5

2019-08-01

Cell

Abstract:Most patients diagnosed with resected pancreatic adenocarcinoma (PDAC) survive less than 5 years, but a minor subset survives longer. Here, we dissect the role of the tumor microbiota and the immune system in influencing long-term survival. Using 16S rRNA gene sequencing, we analyzed the tumor microbiome composition in PDAC patients with short-term survival (STS) and long-term survival (LTS). We found higher alpha-diversity in the tumor microbiome of LTS patients and identified an intra-tumoral microbiome signature ( Pseudoxanthomonas- Streptomyces- Saccharopolyspora- Bacillus clausii) highly predictive of long-term survivorship in both discovery and validation cohorts. Through human-into-mice fecal microbiota transplantation (FMT) experiments from STS, LTS, or control donors, we were able to differentially modulate the tumor microbiome and affect tumor growth as well as tumor immune infiltration. Our study demonstrates that PDAC microbiome composition, which cross-talks to the gut microbiome, influences the host immune response and natural history of the disease.

cell biology,biochemistry & molecular biology
The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer

Meghna Basu,Lisa-Marie Philipp,John F Baines,Susanne Sebens

DOI: https://doi.org/10.3389/fonc.2021.740606

2021-09-23

Abstract:Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant cancers. It is characterized by a poor prognosis with a 5-year survival rate of only around 10% and an ongoing increase in death rate. Due to the lack of early and specific symptoms, most patients are diagnosed at an advanced or even metastasized stage, essentially limiting curative treatment options. However, even curative resection of the primary tumor and adjuvant therapy often fails to provide a long-term survival benefit. One reason for this dismal situation can be seen in the evolution of therapy resistances. Furthermore, PDAC is characterized by high intratumor heterogeneity, pointing towards an abundance of cancer stem cells (CSCs), which are regarded as essential for tumor initiation and drug resistance. Additionally, it was shown that the gut microbiome is altered in PDAC patients, promotes Epithelial-Mesenchymal-Transition (EMT), determines responses towards chemotherapy, and affects survival in PDAC patients. Given the established links between CSCs and EMT as well as drug resistance, and the emerging role of the microbiome in PDAC, we postulate that the composition of the microbiome of PDAC patients is a critical determinant for the abundance and plasticity of CSC populations and thus tumor heterogeneity in PDAC. Unravelling this complex interplay might pave the way for novel treatment strategies.
Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma

Nina Pfisterer,Christoph Ammer-Herrmenau,Kai Antweiler,Stefan Küffer,Volker Ellenrieder,Albrecht Neesse

DOI: https://doi.org/10.1016/j.pan.2023.07.008

IF: 3.977

Pancreatology

Abstract:Background: Emerging evidence has recently revealed a prominent role of the microbiome in pancreatic ductal adenocarcinoma (PDAC). However, while most observations were made in patients, mouse models still require a precise characterization of their disease-related microbiome to employ them for mechanistic and interventional preclinical studies. Methods: To investigate the fecal and tumoral microbiome of LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) and control (CTRL) mice, Oxford Nanopore sequencing was applied. Feces were collected from 10 KPC mice and 10 CTRLs at 3 timepoints (6 weeks, 12 weeks, and when tumor-bearing (KPC) or 6 months (CTRL), respectively). Metagenomic sequencing was performed on feces DNA. KPC tumor and healthy pancreas DNA samples were subjected to 16S rRNA gene sequencing. Bacterial marker components were detected in KPC tumor tissue over time by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Results: Murine fecal samples showed a significantly different microbiome compared to age-matched healthy CTRLs regarding beta diversity (p = 0.001, R2 = 0.2-0.25 for Bray-Curtis). Adjusted human PDAC classifiers predicted disease status from feces of KPC mice achieving area under the receiver operating characteristic (AUROC) values of 80%. Furthermore, KPC tumors harbored significantly more bacterial components than healthy pancreas. Also the microbial composition differs significantly between KPC tumors and healthy pancreas tissue (p = 0.042 for Bray-Curtis). Microbiota found highly abundant in human PDAC samples were considerably more abundant in KPC tumors as compared to healthy pancreas samples (p-value <0.001). Conclusion: KPC fecal samples show similarities with the microbial composition of stool samples from human PDAC patients.
Microbiome and pancreatic cancer: A comprehensive topic review of literature

Natalie Ertz-Archambault,Paul Keim,Daniel Von Hoff

DOI: https://doi.org/10.3748/wjg.v23.i10.1899

IF: 5.374

2017-01-01

World Journal of Gastroenterology

Abstract:AIM: To review microbiome alterations associated with pancreatic cancer, its potential utility in diagnostics, risk assessment, and influence on disease outcomes.METHODS: A comprehensive literature review was conducted by all-inclusive topic review from PubMed, MEDLINE, and Web of Science. The last search was performed in October 2016.RESULTS: Diverse microbiome alterations exist among several body sites including oral, gut, and pancreatic tissue, in patients with pancreatic cancer compared to healthy populations.CONCLUSION: Pilot study successes in non-invasive screening strategies warrant further investigation for future translational application in early diagnostics and to learn modifiable risk factors relevant to disease prevention. Pre-clinical investigations exist in other tumor types that suggest microbiome manipulation provides opportunity to favorably transform cancer response to existing treatment protocols and improve survival.

gastroenterology & hepatology

Pancreatic Fungal Communities Are Linked to Pancreatic Cancer.

Microbiota Regulates Pancreatic Cancer Carcinogenesis through Altered Immune Response.

Fungi accelerate pancreatic cancer

A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors

Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations

Fungi complements cancer

The Microbiota and Microbiome in Pancreatic Cancer: More Influential Than Expected

Microbiome and pancreatic ductal adenocarcinoma

Micro- and Mycobiota Dysbiosis in Pancreatic Ductal Adenocarcinoma Development

Intratumour microbiome of pancreatic cancer

Abstract 2176: Differences in gut microbial composition alter pancreatic tumorigenesis

Mycobiome and Cancer: What Is the Evidence?

Microbiomes in pancreatic cancer can be an accomplice or a weapon

Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models

Fusobacterium nucleatum induces pancreatic cancer cell proliferation and migration by regulating host autocrine and paracrine signaling

Revisiting the intrinsic mycobiome in pancreatic cancer

An investigation for phylogenetic characterization of human Pancreatic cancer microbiome by 16SrDNA Sequencing and Bioinformatics techniques

Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

The Microbiome Tumor Axis: How the Microbiome Could Contribute to Clonal Heterogeneity and Disease Outcome in Pancreatic Cancer

Dynamics of intestinal and intratumoral microbiome signatures in genetically engineered mice and human pancreatic ductal adenocarcinoma

Microbiome and pancreatic cancer: A comprehensive topic review of literature